Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

Sorafenib is approved as a standard therapy for advanced hepatocellular carcinoma (HCC), but its clinical application is limited due to moderate therapeutic efficacy and high incidence of acquired resistance r...

Source: Journal of Experimental and Clinical Cancer Research - May 31, 2019 Category: Cancer & Oncology Authors: Ning Zheng, Weiqun Liu, Bifei Li, Huifang Nie, Jian Liu, Yunlong Cheng, Jichuang Wang, Haiyan Dong and Lee Jia Tags: Research Source Type: research